Hologic Announces Completion of Term Loan B Refinancing Interest rate on Term Loan B reduced by up to 50 basis points

BEDFORD, Mass., Feb. 26, 2014 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products with an emphasis on serving the healthcare needs of women, announced today that the Company completed a refinancing of its senior secured tranche B term loan facility (Existing Term Loan B) under the Company's Credit and Guaranty Agreement (Credit Agreement) dated August 1, 2012.

On February 26, 2014, the Company and several of its domestic subsidiaries (Guarantors), together with Goldman Sachs Bank USA, as administrative and collateral agent, and the lenders party thereto entered into Refinancing Amendment No. 3 (Credit Agreement Amendment 3) to the Credit Agreement.

The Credit Agreement Amendment 3 evidences, among other things, the refinancing of the Company's Existing Term Loan B with a maturity date of August 1, 2019, with a new senior secured tranche B term loan facility (New Term Loan B) with an issue price of 99.875% of the principal amount of the Existing Term Loan B (subject also to the prepayment referenced below). The Credit Agreement Amendment 3 will result in up to a 50 basis point reduction in the interest rate on the New Term Loan B as of the Credit Agreement Amendment 3 closing date (from 2.75% plus LIBOR with a 1.00% floor to 2.50% plus LIBOR with a 0.75% floor). In addition, the Company voluntarily prepaid $25 million of the New Term Loan B on February 26, 2014. Immediately following this prepayment, the principal amount outstanding on the New Term Loan B is approximately $1.15 billion.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Investor Relations and Media Contacts:


Deborah R. Gordon 

Al Kildani

Vice President, Investor Relations

Senior Director, Investor Relations

(781) 999-7716

(858) 410-8653

deborah.gordon@hologic.com 

al.kildani@hologic.com

SOURCE Hologic, Inc.



RELATED LINKS
http://www.hologic.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.